Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis

Berglund, Mattias; Thunberg, Ulf; Amini, Rose‐Marie; Book, Majlis; Roos, Göran; Erlanson, Martin; Linderoth, Johan; Dictor, Michael; Jerkeman, Mats; Cavallin‐Ståhl, Eva; Sundström, Christer; Rehn-Eriksson, Suzanne; Backlin, Carin; Hagberg, Hans; Rosenquist, Richard; Enblad, Gunilla

doi:10.1038/modpathol.3800396

Cited by 175 publications

(207 citation statements)

References 42 publications

Supporting

Mentioning

171

Contrasting

Unclassified

Order By: Relevance

“…Finally, we observed 14% of CD10 positivity suggesting a large amount of PBL of nongerminal center B-cell lymphoma (non-GCB), as shown by Yoshida et al who observed 15/ 15 non-GCB PBL [23]. Our results are therefore concordant with those that have been previously reported in PBL, as in DLBCLs [28,31,32,34,35,37] (Table III).…”

Section: Discussionsupporting

confidence: 92%

“…We found 71% of Bcl-2-positive tumor samples when more than 30% of the tumor cells were positive. This result was concordant with the 10/15 Bcl-2-positive PBL reported by Yoshiba et al [23] and the proportion of Bcl-2-positive DLBCLs reported in the literature [25][26][27][28][29][30][31][32][33][34][35][36]. Finally, we observed 14% of CD10 positivity suggesting a large amount of PBL of nongerminal center B-cell lymphoma (non-GCB), as shown by Yoshida et al who observed 15/ 15 non-GCB PBL [23].…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Primary breast non‐Hodgkin's lymphoma: A large single center study of initial characteristics, natural history, and prognostic factors

et al. 2009

View full text Add to dashboard Cite

The aims of this study were to define the initial pathological and clinical characteristics, and prognostic factors of patients with primary breast malignant lymphoma (PBL). All patients treated at the Institut Curie for lymphoma with breast involvement were reviewed. A pathological review of all cases was performed. Fortyfive cases were selected in whom 38 cases were of diffuse large B-cell lymphoma. A complete analysis was then performed on these 38 patients. Twenty out of 28 cases (71%) of cases were Bcl-2 positive and four out of 28 (14%) had a CD10 positive staining. Peculiar initial characteristics showed nodal involvement in 58% of the cases and two or more extra-nodal sites in 31% of the cases. Among the 37 patients for whom all data were available, and according to the International Prognostic Index, 19 patients (51%) were classified in the low-risk group, 5 cases (14%) in the low-to intermediate-risk group, 6 patients (16%) in the intermediate-to high-risk group, and 7 (19%) case in the high-risk group. At the end of initial therapy, 34 patients (89%) achieved CR. With a median follow-up of 96 months, 18 patients (47%) relapsed of whom 3 had a relapse in central nervous system site. The 5-year disease-free (DFS) and overall survivals (OS) were 54% and 61%, respectively. In multivariate analysis, the presence of 2 or more extranodal sites was prognostic for lower DFS (P 5 0.0008) and OS (P 5 0.09), and a performance status ‡1 was prognostic for lower OS (P 5 0.005). Finally, when our series was compared with a historical series of 111 patients with aggressive nodal lymphomas, we observed significant lower survival rates in localized PBL (P < 0.03). Initial breast localization has a pejorative impact on the outcome of patients with Non-Hodgkin's Lymphoma (NHL), with an impressive adverse influence of additional extranodal sites. These results suggest a specific management of NHL with breast involvement. Am. J. Hematol. 84:133-139, 2009. V

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 91%

Primary breast non‐Hodgkin's lymphoma: A large single center study of initial characteristics, natural history, and prognostic factors

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Harada et al, 1999;Braaten et al, 2003;Berglund et al, 2005;Sjo et al, 2007), whereas nine studies did not report any significant difference in OS between positive and negative BCL-6 expression in DLBCL patients (e.g. Colomo et al, 2003;Kojima et al, 2006;Lin et al, 2006;Muris et al, 2006).…”

Section: Discussionmentioning

confidence: 99%

“…BCL-6 is a zinc-finger transcriptional repressor selectively expressed in germinal center B-cells (Phan and Dalla-Favera, 2004), and has been consistently associated with a better OS (Berglund et al, 2005;Zinzani et al, 2005;Kojima et al, 2006;Sjo et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of BCL-6, CD10, CD138 and MUM-1 Expression in Diffuse Large B-Cell Lymphoma patients: CD138 is a Marker of Poor Prognosis

Bodoor

Matalka²,

Hayajneh³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The diffuse large B-cell lymphoma (DLBCL) encompasses two major groups of tumors with uneven survival outcomes -germinal center B-cell (GCB) and non-germinal center B-cell (non-GCB). In the present study, we investigated the expression of GCB markers (BCL-6 and CD10) and non-GCB markers (CD138 and MUM-1) in an effort to evaluate their prognostic value. Paraffin-embedded tumor biopsies of 46 Jordanian DLBCL patients were analyzed, retrospectively, by immunohistochemistry to investigate the expression of BCL-6, CD10, CD138 and MUM-1. In addition, survival curves were calculated with reference to marker expression, age, sex and nodal involvement. Positive expression of BCL-6, CD10, CD138 and MUM-1 was shown in 78%, 61%, 39% and 91% of the cases, respectively, that of BCL-6 being associated with better overall survival (p = 0.02), whereas positive CD138 was linked with poor overall survival (p = 0.01). The expression of CD10 and MUM-1 had no impact on the overall survival. Among the clinical characteristics studied, diagnosis at an early age, nodal involvement and maleness were associated with a higher overall survival for DLBCL patients. Our results underline the importance of BCL-6 as a marker of better prognosis and CD138 as a marker of poor prognosis for DLBCL patients.

show abstract

“…MUM1 positive cases are assigned to the nongerminal center subtype and MUM1 negative tumors to the germinal center subtype. Several studies have investigated the validity of using this stratification scheme in other extranodal diffuse large B-cell lymphomas; [13][14][15][16][17][18] however, it remains unclear whether primary central nervous system diffuse large B-cell lymphomas can be subdivided into these same two prognostic groups.…”

mentioning

confidence: 99%

Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases

et al. 2010

View full text Add to dashboard Cite

Primary central nervous system lymphomas are rare neoplasms characterized by a dismal prognosis relative to other extranodal lymphomas. Approximately 98% of primary central nervous system lymphomas are of B-cell origin, and most belong to the diffuse large B-cell type. Recently, diffuse large B-cell lymphomas have been subcategorized into germinal center and nongerminal center types based on gene expression profiles and immunohistochemical expression of CD10, Bcl-6, and MUM1. Studies have shown that the overall survival rate of the germinal center group is better than that of the nongerminal center lymphomas. In this study, 31 cases of primary central nervous system lymphomas of the diffuse large B-cell type were retrieved, reviewed, and immunostained for CD10, Bcl-6, MUM1, and Ki-67. Subclassification was carried out as described earlier, where CD10 and/or Bcl-6 positivity and negativity for MUM1 were considered characteristic of germinal center subtype and the opposite expression of nongerminal center subtype. Furthermore, the proliferative activity was semiquantitatively assessed using percent positive cells staining with Ki-67. Of the 31 cases examined, 26 (84%) were found to belong to the nongerminal center type. The Ki-67 index in these 26 cases ranged from 30 to 90% (mean, 69%). Five cases were categorized as the germinal center subtype. They had an Ki-67 index between 70 and 90% (mean, 78%). Interestingly, none of our patients were known to be HIV positive. One patient had a 10-year history of orthotopic liver transplant. We also performed fluorescence in situ hybridization analysis on formalin-fixed material and found that 38% of the cases where tissue was available had abnormalities of MYC/ IGH and/or IGH/BCL2. We conclude that most primary central nervous system diffuse large B-cell lymphomas are of the nongerminal center origin. Regardless of the germinal center status, all cases showed a high proliferative rate. A statistically significant difference in the overall survival between the two groups was not seen.

show abstract

Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis

Cited by 175 publications

References 42 publications

Primary breast non‐Hodgkin's lymphoma: A large single center study of initial characteristics, natural history, and prognostic factors

Primary breast non‐Hodgkin's lymphoma: A large single center study of initial characteristics, natural history, and prognostic factors

Evaluation of BCL-6, CD10, CD138 and MUM-1 Expression in Diffuse Large B-Cell Lymphoma patients: CD138 is a Marker of Poor Prognosis

Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases

Contact Info

Product

Resources

About